Is Mangalam Drugs And Organics a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Mangalam Drugs And Organics Ltd is a average quality company .

Is Mangalam Drugs And Organics undervalued or overvalued?

The key valuation ratios of Mangalam Drugs And Organics Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Mangalam Drugs And Organics share price return in the past 10 years?

Mangalam Drugs And Organics Ltd share price has appreciated 32.9% annually (CAGR) over the past ten years.

Is Mangalam Drugs And Organics a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Mangalam Drugs And Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Mangalam Drugs And Organics?

The latest standalone P/E ratio of Mangalam Drugs And Organics as of 19-Apr-2024 is 0.00.

What is the P/B ratio of Mangalam Drugs And Organics?

The latest standalone P/B ratio of Mangalam Drugs And Organics as of 19-Apr-2024 is 1.13.

What is the 52-week high and low of Mangalam Drugs And Organics?

The 52-week high of Mangalam Drugs And Organics is Rs. 132.40 and the 52-week low is Rs. 85.16.

Mangalam Drugs And Organics Ltd - Stock Valuation and Financial Performance

Name: Mangalam Drugs And Organics
Brand: Mangalam Drugs And Organics

BSE: 532637 | NSE: MANGALAM | Pharmaceuticals & Drugs | Small Cap

Place order

Mangalam Drugs&Org. Share Price

₹99.66 0.17 0.17%
as on 19-Apr'24 16:01

10 Year X-Ray of Mangalam Drugs&Org.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	3.8%	12.9%	19.8%	22%	17.1%	-1.2%	9.9%	19.8%	12.9%	4.5%	-
Value Creation Index ⓘ	-0.7	-0.1	0.4	0.6	0.2	-1.1	-0.3	0.4	-0.1	-0.7	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	123	221	295	303	279	228	282	385	451	372	356
Sales YoY Gr.	-	80%	33.8%	2.7%	-7.8%	-18.5%	24.1%	36.3%	17.3%	-17.5%	-
Adj EPS ⓘ	-2.3	4.7	11.2	14.5	12.3	-5.1	5.2	17.7	12.4	0.8	-10.7
YoY Gr.	-	NA	138.9%	29.3%	-15.4%	-141.6%	NA	240.5%	-29.9%	-93.5%	-
BVPS (₹) ⓘ	17.6	22.3	36.9	54.2	65.6	60.4	65.7	82.6	95.1	96	88.1
Adj Net Profit ⓘ	-3.1	6.2	16.2	23	19.4	-8.1	8.2	28	19.6	1.3	-17
Cash Flow from Ops. ⓘ	7.5	14	21.8	42.8	24.6	21.7	30.6	27.6	25.7	39.5	-
Debt/CF from Ops. ⓘ	10.3	5.6	2.7	1.5	2.8	2.9	1.6	2.3	3.1	1.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	13.1%	5.9%	9.7%	-17.5%
Adj EPS ⓘ	NA	-42.1%	-46.4%	-93.5%
BVPSⓘ	20.7%	7.9%	13.5%	0.9%
Share Price	32.9%	12.3%	-7%	-10.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	-12.4	23.6	35.5	31.2	20.5	-8.1	8.2	23.8	13.9	0.8	-11.7
Op. Profit Mgn % ⓘ	7.9	9.3	12.8	15.5	16.8	4.3	8.4	15.1	10.9	6.9	1.7
Net Profit Mgn % ⓘ	-2.5	2.8	5.5	7.6	7	-3.6	2.9	7.3	4.3	0.3	-4.8
Debt to Equity ⓘ	3.3	2.7	1.1	0.8	0.7	0.7	0.5	0.5	0.5	0.5	-
Working Cap Days ⓘ	188	152	130	114	130	162	136	126	131	192	117
Cash Conv. Cycle ⓘ	123	67	56	58	62	83	47	48	69	95	18

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.49

Return on Equity is Poor

Sales growth has been subdued in last 3 years 9.65%

Sales growth is not so good in last 4 quarters at -4.11%

Latest Financials - Mangalam Drugs And Organics Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-10.7	-
TTM Sales (₹ Cr.)	356	-
BVPS (₹.) ⓘ	88.1	-
Reserves (₹ Cr.) ⓘ	124	-
P/BV ⓘ	1.13	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	85.16 / 132.40
All Time Low / High (₹)	3.43 / 441.50
Market Cap (₹ Cr.)	158
Equity (₹ Cr.)	15.8
Face Value (₹)	10
Industry PE ⓘ	47.2

Management X-Ray of Mangalam Drugs&Org.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

11.59

16.88

19.98

16.97

16.22

16.65

20.93

20.04

17.52

18.08

* Pledged shares as % of Promoter's holding (%)

Valuation of Mangalam Drugs&Org.

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Mangalam Drugs&Org.

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	123	221	295	303	279	228	282	385	451	372
Operating Expenses ⓘ	113	200	257	257	233	218	259	327	402	347
Manufacturing Costs	18	21	22	23	29	27	24	30	42	45
Material Costs	78	157	204	196	167	154	195	252	307	251
Employee Cost	10	11	14	19	23	26	26	30	37	35
Other Costs ⓘ	7	11	17	19	14	12	13	15	16	16
Operating Profit ⓘ	10	20	38	46	47	10	24	58	49	26
Operating Profit Margin (%)	7.8%	9.2%	12.7%	15.2%	16.8%	4.3%	8.4%	15.1%	10.9%	6.9%
Other Income ⓘ	0	0	0	0	1	0	1	0	0	0
Interest ⓘ	10	10	9	10	12	9	10	9	11	13
Depreciation ⓘ	4	4	4	5	7	7	8	9	10	11
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	-4	6	24	31	29	-6	6	40	28	2
Tax ⓘ	-1	0	8	9	9	2	-2	12	8	1
Profit After Tax	-3	6	16	22	20	-8	8	28	20	1
PAT Margin (%)	-2.5%	2.8%	5.4%	7.4%	7.1%	-3.5%	2.9%	7.3%	4.4%	0.3%
Adjusted EPS (₹)	-2.3	4.7	11.2	14.1	12.6	-5.1	5.2	17.7	12.4	0.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	4%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	23	29	53	86	104	96	104	131	151	152
Share Capital ⓘ	13	13	14	16	16	16	16	16	16	16
Reserves ⓘ	10	16	39	70	88	80	88	115	135	136
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	72	71	52	58	62	59	46	58	72	68
Long Term Debt	40	39	17	17	11	9	4	7	25	19
Short Term Debt	31	32	35	41	51	51	42	51	47	50
Trade Payables	21	55	21	21	38	32	57	43	55	97
Others Liabilities ⓘ	10	15	34	25	23	24	24	32	51	42
Total Liabilities ⓘ	125	170	160	190	227	211	231	264	328	360
Fixed Assets
Gross Block	88	92	98	140	156	165	171	197	224	241
Accumulated Depreciation	35	39	43	48	54	62	70	79	89	99
Net Fixed Assetsⓘ	53	53	54	93	102	103	101	118	135	142
CWIP ⓘ	0	0	5	0	0	0	1	6	6	9
Investmentsⓘ	0	0	0	2	0	0	0	0	0	0
Inventories	36	57	47	37	60	73	65	59	117	137
Trade Receivables	30	44	30	37	45	18	40	54	46	47
Cash Equivalents	0	1	0	1	0	1	2	1	2	3
Others Assetsⓘ	6	14	22	21	19	15	22	26	22	21
Total Assets ⓘ	125	170	160	190	227	211	231	264	328	360

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	7	14	22	43	25	22	31	28	26	40
PBT ⓘ	-4	6	24	31	29	-6	6	40	28	2
Adjustment ⓘ	14	15	14	17	18	16	19	17	22	24
Changes in Working Capital ⓘ	-2	-6	-12	1	-17	11	6	-20	-16	13
Tax Paid ⓘ	0	0	-4	-7	-6	0	0	-9	-9	0
Cash Flow From Investing Activity ⓘ	-2	-4	-11	-39	-16	-9	-7	-31	-27	-22
Capex	-2	-4	-11	-39	-16	-9	-7	-31	-28	-22
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activityⓘ	-5	-10	-11	-3	-9	-11	-23	3	3	-17
Net Proceeds from Shares ⓘ	0	0	0	1	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	2	0	-22	0	-6	-3	-4	3	18	-6
Interest Paid ⓘ	-10	-10	-9	-10	-12	-9	-10	-9	-11	-13
Dividend Paid ⓘ	0	0	0	0	-1	0	0	0	0	0
Others ⓘ	3	0	20	6	9	0	-9	9	-4	2
Net Cash Flow ⓘ	0	1	0	0	0	1	0	-1	1	1

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	-12.28	23.36	38.91	32.11	20.99	-8.05	8.27	23.83	13.97	0.84
ROCE (%)	5.86	15.69	29.14	30.18	25.35	1.76	10.66	28.01	18.34	6.56
Asset Turnover Ratio	1.06	1.53	1.84	1.79	1.48	1.18	1.42	1.56	1.52	1.08
PAT to CFO Conversion(x)	N/A	2.33	1.38	1.95	1.25	N/A	3.88	1	1.3	40
Working Capital Days
Receivable Days	77	60	45	39	49	44	34	45	41	46
Inventory Days	97	76	63	49	58	94	81	59	71	125
Payable Days	74	88	68	39	64	83	83	72	58	110

Mangalam Drugs And Organics Ltd Stock News

Mangalam Drugs And Organics Ltd FAQs

What is the share price of Mangalam Drugs&Org.?

Company share prices are keep on changing according to the market conditions. The closing price of Mangalam Drugs&Org. on 19-Apr-2024 16:01 is ₹99.66.

What is the market cap of Mangalam Drugs&Org.?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 19-Apr-2024 16:01 the market cap of Mangalam Drugs&Org. stood at ₹157.8.

What is the P/E ratio of Mangalam Drugs&Org.?

The latest P/E ratio of Mangalam Drugs&Org. as of 19-Apr-2024 16:01 is 0.00.

What is the P/B ratio of Mangalam Drugs&Org.?

The latest P/B ratio of Mangalam Drugs&Org. as of 19-Apr-2024 16:01 is 1.13.

What is the 52-week high and low of Mangalam Drugs&Org.?

The 52-week high of Mangalam Drugs&Org. is ₹132.4 and the 52-week low is ₹85.16.

What is the TTM revenue of Mangalam Drugs&Org.?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mangalam Drugs&Org. is ₹355.7 ( Cr.) .

About Mangalam Drugs And Organics Ltd

Mangalam Drugs & Organics Limited (Mangalam) is a part of the MangalamGroup promoted by Dhoot family in 1972 as Advent Pharma PrivateLimited with a view to set up a plant for manufacture of organic andinorganic chemicals. Mangalam Drugs & Organics commmenced its business in 1977.

The company manufactures chemicals such as API perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates at VAPI-Gujarat State. It has a multi-product manufacturing facility and a in-house Research and Development (R&D) Base.

The Company has a diversified product range having synergies in operations and substantial economies of scale. It is amongst the top three manufacturers in India in almost all the products that it manufactures.

Today Mangalam Drugs & Organics enjoys a very strong brand name in the domestic market. It has over two decades of experience in the industry with a very wide and satisfied customer base.

The company has a state of art multi-product manufacturing facilitiesat Vapi in Gujarat and Sangamner in Maharashtra for production of bulkdrugs perfumery chemicals inorganic chemicals and disperse dyesintermediaries with a strong in-house Research and Development base.

Product range of the company includes:

Active Pharma Ingredients (API)

Anti Malarial
Analgesic / Anti Inflammatory
Diuretic
Anti Hypertensive
Anti Convulsant

API Under Development

Intermediates
Antiurolithic

Prefumery / Specialty Chemicals

Phenyl Ethyl Alcohol
Phenyl Ethyl Methyl Ether
Phenyl Ethyl Acetate

Disperse Dye Intermediates

Meta Nitro Aniline (Mna)(99-09-2)
Meta Amino Propionilide (MAP)
Meta Amino Acetanilide (MAA) (162-28-3)
Para Amino Acetanilide (PAA) 122-80-5)
Para Amino Propionilide (PAP) (59690-89-0)
N-Cyano Ethyl Aniline (1075-76-9)
N,N-BIS (2-Hydroxy Ethyl) Meta Chloro Aniline (Mangalam-1) (92-00-2)
N,N-BIS (2-Acetoxy Ethyl) Meta Chloro Aniline (Mangalam -1A) (26692-46-6) etc.

Achievements/ recognition:

Awarded the ISO 9001:2000 Management System Certificate from DNV for Design Development, Manufacture and supply of Bulk Drugs, and Dyes Intermediates.
Received the WHO GMP Certificate for its Bulk Drug manufacturing Plant